You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
多只未有盈利生物股创新高後急吐 康希诺及迈博倒跌12%-13%
阿思达克 05-21 14:32
近期狂炒仍未有任何盈利生物「B类股」今天普遍由高位掉头急吐,康希诺生物-B(06185.HK)承过去连续七天破顶强势,今天再飙升16%高见285.8元(较去年3月上市价22元累飙近12倍)遇阻,午後获利盘涌现,股价掉头曾失守10天线(193.8元),曾急吐23%低见190元,现造216.8元,急吐12%,成交急增至788万股,创逾一个月高,涉资18.47亿元。

迈博药业-B(02181.HK)本周一曾飙升至1.8元创上市新高遇阻反覆回落,今天低见1.25元,现造1.3元,急吐13%,成交1,436万股。信达生物-B(01801.HK)高见46.7元,受制本周二盘中所创上市高位46.8元,掉头低见42元,现造42.4元,倒跌8.1%。

去年底才挂牌的康宁杰瑞制药-B(09966.HK)今早高开见24.15元上市新高遇阻,掉头低见20.6元,现造21.55元,倒跌6.7%。

华领医药-B(02552.HK)日前受制牛熊线,今天股价反覆续吐2.4%报4.95元。诺诚健华-B(09969.HK)再扑昨天盘中所创上市高位16.8元未能成功突破,掉头低见15.22元(刚为10天线),现造15.46元,倒跌4.8%。中国抗体制药-B(03681.HK)高见4.95元创半年高遇阻,掉头低见4.25元,现造4.36元,倒跌1%。上周五才以每股15.36元上市的沛嘉医疗-B(09996.HK)高见31.25元再创上市新高遇阻,掉头低见26.15元,现造27.8元,倒跌5.1%。

不过,君实生物医药-B(01877.HK)继昨天整固後,今天股价再创上市新高,最高见49.7元,现造45.85元,回升4.3%。

至於大股东藉股价反覆探顶以每股127.18元(较昨天收市价折让4.9%)配售6,000万股的高药明生物(02269.HK)由上市高位140.8元掉头连吐第三天,最低见129元,现造131.4元,续吐1.7%,股价失守10天线(132.6元),成交受配股上板带动增至7,508万股。另外,蓝筹中生制药(01177.HK)继昨天升至12.66元受制3月所创52周高位後,今天股价回吐4%报11.9元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account